Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on April 1, 2009. The filing details a strategic partnership and capital raise involving Cadila Pharmaceuticals Ltd. and its subsidiary, Satellite Overseas (Holdings) Limited (SOHL). The report covers events occurring on March 31 and April 1, 2009, including the election of a new director and the execution of material agreements.
Key Financial Metrics and Capital Raise
- Capital Raised: Novavax sold 12.5 million shares of Common Stock to SOHL at $0.88 per share.
- Gross Proceeds: $11 million.
- Net Proceeds: Approximately $10.65 million after estimated offering expenses.
- Joint Venture Funding: Cadila agreed to contribute approximately $8 million over three years to support the new Joint Venture (JV) operations.
- Service Commitment: A Master Services Agreement includes a minimum spend threshold of $7.5 million over three years.
Material Changes and Agreements
On March 31, 2009, Novavax entered into three primary agreements with Cadila and SOHL:
- Joint Venture Agreement (JVA): Established a JV (80% owned by Cadila) to develop and commercialize Novavax's seasonal influenza VLP-based vaccine and Cadila's therapeutic candidates in India. Novavax will also contribute technology for hepatitis E and chikungunya fever vaccines. The JV requires approval from India's Foreign Investment Promotion Board (FIPB) before issuing shares to Novavax.
- Stock Purchase Agreement (SPA): SOHL purchased 12.5 million shares. The agreement grants SOHL a right of first refusal to purchase a pro-rata portion of any future stock sales as long as they own more than 5% of outstanding shares. SOHL also received resale registration rights.
- Master Services Agreement: Novavax may engage Cadila for biologics research, development, and manufacturing services in India. If services provided fall below $7.5 million by the third anniversary, Novavax must pay a shortfall fee: $2.0 million for the first $2.0 million of shortfall, plus 50% of any amount exceeding $2.0 million.
Effective April 1, 2009, the Board of Directors increased in size to eight and elected Dr. Rajiv I. Modi, Managing Director of Cadila, as a Class I director. Dr. Modi has an indirect material interest in the agreements due to his family's ownership in Cadila.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or revenue projections for future periods. However, the agreements outline the following operational outlook and risks:
- Regulatory Risk: The Joint Venture cannot issue shares to Novavax until it obtains approval from India's FIPB.
- Financial Contingency: Novavax faces a potential cash outflow obligation under the Master Services Agreement if Cadila does not utilize at least $7.5 million in services over three years.
- Dilution: The SPA includes provisions that may affect future capital raising activities if SOHL exercises its pro-rata purchase rights.
Key Facts for Investor Verification
- Verify the status of the FIPB approval required for the Joint Venture to issue shares to Novavax.
- Monitor the utilization of services under the Master Services Agreement to assess potential shortfall payment obligations.
- Review the impact of SOHL's pro-rata purchase rights on future equity financing flexibility.
- Confirm the timeline for the Joint Venture's clinical testing and registration activities in India.